Want to see SER full AI Analyst Report?
SER Stock Chart & Stats
$2.07
-$0.02(-0.96%)
At close: 4:00 PM EDT
$2.07
-$0.02(-0.96%)
Day’s Range― - ―
52-Week Range$1.22 - $7.92
Previous CloseN/A
Volume44.32K
Average Volume (3M)24.47K
Market Cap
$30.00M
Enterprise Value$93.00K
Total Cash (Recent Filing)$24.53M
Total Debt (Recent Filing)$3.17M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Aug 07, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding14,997,505
10 Day Avg. Volume14,098
30 Day Avg. Volume24,472
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-526.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.72
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.50Price Target Upside358.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Polymer Drug-delivery PlatformA platform approach provides durable business optionality: the polymer technology can be paired with multiple drugs and disease areas, enabling licensing, partnerships and diversified development programs that reduce single-product dependency and support long-term value creation.
Conservative Balance Sheet With Very Low DebtLow leverage and a meaningful asset base preserve financial flexibility for an R&D-heavy biotech. A conservative capital structure reduces interest burden and creditor risk, improving capacity to raise or allocate capital for trials without acute solvency pressure.
Expanded Authorized Shares Boost Financing FlexibilityBoard-approved authority to issue more shares and expand incentives is a structural enabler: it allows the company to fund development, pursue collaborations, or execute acquisitions using equity, supporting sustained R&D investment when cash generation is limited.
Bears Say
Sustained High Cash BurnMaterial and ongoing negative cash flow underscores reliance on external funding. Persistent burn erodes runway, increases frequency of financing events, and forces capital-allocation tradeoffs that can delay programs or dilute investors, constraining long-term operational independence.
Minimal Revenue With Large Net LossesExtremely low revenue and substantial losses limit operating leverage and the ability to self-fund growth. Until clinical progress converts into sustainable revenues or high-value partnerships, the business depends on financing, increasing execution and commercialization risk over the medium term.
Meaningful Dilution Risk From Equity ExpansionsWhile enabling financing, the large increase in authorized shares and expanded incentive plan creates a durable dilution overhang. Future equity issuances to fund R&D or conversions can materially dilute existing holders and affect per-share economics and incentive alignment.
Serina Therapeutics News
SER FAQ
What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was $1.22 and its highest was $7.92 in the past 12 months.
What is Serina Therapeutics’s market cap?
Serina Therapeutics’s market cap is $30.00M.
When is Serina Therapeutics’s upcoming earnings report date?
Serina Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 2 days.
How were Serina Therapeutics’s earnings last quarter?
Serina Therapeutics released its earnings results on May 14, 2026. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.44 by -$0.14.
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Undervalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate is -0.47.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 14,997,505 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Serina Therapeutics reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.44. Following the earnings report the stock price went down -4.651%.
Which hedge fund is a major shareholder of Serina Therapeutics?
Currently, no hedge funds are holding shares in SER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
SER Stock 12 Month Forecast
Average Price Target
$9.50
▲(358.94% Upside)
Technical Analysis
Outlook Therapeutics
―
Skye Bioscience
―
Celularity
―
Barinthus Biotherapeutics
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
59.01% Insiders
1.32% Mutual Funds
0.13% Other Institutional Investors
38.45% Public Companies and
Individual Investors